PT - JOURNAL ARTICLE AU - Narayanan, Sai AU - Ritchey, John C AU - Patil, Girish AU - Narasaraju, Teluguakula AU - More, Sunil AU - Malayer, Jerry AU - Saliki, Jeremiah AU - Kaul, Anil AU - Ramachandran, Akhilesh TI - SARS-CoV-2 genomes from Oklahoma, USA AID - 10.1101/2020.09.15.20195420 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.15.20195420 4099 - http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195420.short 4100 - http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195420.full AB - Genomic sequencing has played a major role in understanding the pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the current pandemic, it is essential that SARS-CoV-2 viruses are sequenced regularly to determine mutations and genomic modifications in different geographical locations. In this study we sequenced SARS-CoV-2 from 5 clinical samples obtained in Oklahoma, USA during different time points of pandemic presence in the state. One sample from the initial days of the pandemic in the state and 4 during the peak in Oklahoma were sequenced. Previously reported mutations including D614G in S gene, P4715L in ORF1ab, S194L, R203K and G204R in N gene were identified in the genomes sequenced in this study. Possible novel mutations were also detected such as G1167V in S gene, A6269S and P3371S in ORF1ab, T28I in ORF7b, G96R in ORF8. Phylogenetic analysis of the genomes showed similarity to viruses from across the globe. These novel mutations and phylogenetic analysis emphasize the contagious nature of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by FDA CVM VET-LIRN.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (Application number: IRB-20-357) at Oklahoma State University, Stillwater OK 74078, USA.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data from the study are available in GISAID and GenBank database as mentioned in the manuscript